Publications 2024

Druckrey-Fiskaaen KT, Vold JH, Madebo T, Midgard H, Dalgard O, Leiva RA, Fadnes LT, INTRO-HCV Study Group (2024)
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
Subst Abuse Treat Prev Policy, 19 (1), 21
DOI 10.1186/s13011-024-00603-z, PubMed 38532435

Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, Haug A, Tveter I, Bjørnestad R, Olsen IC, Finbråten AK, Dalgard O (2024)
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203

Publications 2023

Malme KB, Ulstein K, Finbråten AK, Wüsthoff LEC, Kielland KB, Hauge J, Dalgard O, Midgard H (2023)
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
Int J Drug Policy, 116, 104044
DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914

Opheim E, Dalgard O, Ulstein K, Sørli H, Backe Ø, Foshaug T, Couëssurel Wüsthoff LE, Midgard H (2023)
Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs
Int J Drug Policy, 123, 104279
DOI 10.1016/j.drugpo.2023.104279, PubMed 38061225

Polaris Observatory Collaborators (2023)
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
Lancet Gastroenterol Hepatol, 8 (10), 879-907
DOI 10.1016/S2468-1253(23)00197-8, PubMed 37517414

Publications 2022

Haukeland JW, Midgard H, Konopski Z, Sarna VK, Grøtta OJ, Kløw NE (2022)
[Transjugular intrahepatic portosystemic shunt for portal hypertension]
Tidsskr Nor Laegeforen, 142 (14)
DOI 10.4045/tidsskr.21.0911, PubMed 36226423

Midgard H, Bjørnestad R, Egeland M, Dahl E, Finbråten AK, Kielland KB, Blindheim M, Dalgard O (2022)
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs
Liver Int, 42 (6), 1268-1277
DOI 10.1111/liv.15266, PubMed 35362660

Polaris Observatory HCV Collaborators (2022)
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Lancet Gastroenterol Hepatol, 7 (5), 396-415
DOI 10.1016/S2468-1253(21)00472-6, PubMed 35180382

Publications 2021

Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G (2021)
Hepatitis C reinfection in former and active injecting drug users in Belgium
Harm Reduct J, 18 (1), 102
DOI 10.1186/s12954-021-00552-x, PubMed 34641896

Dalgard O, Midgard H, Kielland KB (2021)
Hepatitis C in Iceland: a milestone for global elimination
Lancet Gastroenterol Hepatol, 6 (8), 599-600
DOI 10.1016/S2468-1253(21)00182-5, PubMed 34171268

Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2021)
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
PLoS Med, 18 (6), e1003653
DOI 10.1371/journal.pmed.1003653, PubMed 34061883

Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Int J Drug Policy, 96, 103165
DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182

Publications 2020

Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H (2020)
Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
PLoS One, 15 (3), e0230263
DOI 10.1371/journal.pone.0230263, PubMed 32163489

Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O (2020)
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
Trials, 21 (1), 524
DOI 10.1186/s13063-020-04434-8, PubMed 32539853

Publications 2019

Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2019)
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
BMC Infect Dis, 19 (1), 943
DOI 10.1186/s12879-019-4598-7, PubMed 31703669

Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J (2019)
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
J Hepatol, 72 (4), 643-657
DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345

Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV (2019)
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
Clin Infect Dis, 69 (12), 2218-2227
DOI 10.1093/cid/ciz714, PubMed 31352481

Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O (2019)
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
Scand J Gastroenterol, 54 (9), 1172-1175
DOI 10.1080/00365521.2019.1643403, PubMed 31479286

Øvrehus ALH, Midgard H (2019)
How can we achieve WHO's elimination target for hepatitis C incidence?
Lancet Gastroenterol Hepatol, 4 (6), 415-417
DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687

Publications 2018

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2018)
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Liver Int, 39 (1), 20-30
DOI 10.1111/liv.13949, PubMed 30157316

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M (2018)
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
J Hepatol, 68 (3), 402-411
DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808

Midgard H (2018)
Hepatitis C in drug addicts
Tidsskr. Nor. Laegeforen., 138 (13), 1243

Midgard H, Kielland KB, Dalgard O (2018)
[Elimination of hepatitis C is possible]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0099, PubMed 29663789

Midgard H, Kielland KB, Dalgard O (2018)
Elimination of Hepatitis C is possible
Tidsskr. Nor. Laegeforen., 138 (7), 630-633

Publications 2017

Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T (2017)
Increased hope following successful treatment for hepatitis C infection
J Adv Nurs, 74 (3), 724-733
DOI 10.1111/jan.13487, PubMed 29082540

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J, ACTIVATE Study Group (2017)
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
BMC Infect Dis, 17 (1), 420
DOI 10.1186/s12879-017-2517-3, PubMed 28610605

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I et al. (2017)
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Int J Drug Policy, 47, 51-60
DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ, ACTIVATE Study Group (2017)
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Int J Drug Policy, 47, 177-186
DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J, ACTIVATE Study Group (2017)
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Int J Drug Policy, 47, 230-238
DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998

Publications 2016

Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016)
Hepatitis C reinfection after sustained virological response
J Hepatol, 64 (5), 1020-1026
DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289

Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264

Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O (2016)
HCV epidemiology in high-risk groups and the risk of reinfection
J Hepatol, 65 (1 Suppl), S33-S45
DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987

Publications 2010

Midgard H, Bang C, Raknerud N, Dalgard O (2010)
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Scand J Gastroenterol, 45 (12), 1503-8
DOI 10.3109/00365521.2010.510571, PubMed 20698740